Search
for
Sort by
Research 30 of 1000+
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Hand-Foot and Stump Syndrome to Sorafenib
- Dermatological Manifestations of COVID-19: A Brief Review
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Skin disorders associated with the COVID‐19 pandemic: A review
- Impact of the COVID‐19 pandemic on inpatient dermatology: a multicentre study from Hubei, China
- Targeted Therapy– and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Topoisomerase‐Interacting Agents
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Dermatologic Side Effects of Systemic Targeted Anticancer Therapy
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Prophylaxis and Management of Skin Toxicities
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- The risk of dermatological toxicities of combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma patients: a systematic review and meta-analysis
- Chemotherapy and Cutaneous Drug Reactions
- Hair, Nail, and Skin Changes during COVID 19 Era
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- What is causing this patient's worsening rash after topical corticosteroid use?
- The COVID-19 pandemic and its skin effects
- Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Circumferential acute limited exanthematous pustulosis
- 567 Acute generalized exanthematous pustulosis (AGEP) induced by plaquenil
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- America - A Diversity of Life Styles.